On june 12, 2009, the fda announced that in april 2009, they completed their review of neuropsychiatric events, mood and behavioral changes associated with singulair montelukast and other drugs that act through the leukotriene pathway.

Singulair is indicated for the relief of symptoms of allergic rhinitis seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older .